Company: CORT
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001628280-25-019942
Chunk: 24

Company: CORCEPT THERAPEUTICS INC
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 24
---
4 from $482.4 million in 2023.

• Significantly advanced our clinical development programs:

◦ Submitted a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for our proprietary, selective cortisol modulator, relacorilant, to treat patients with hypercortisolism. Our NDA is based on positive results from our pivotal GRACE trial, Phase 3 GRADIENT trial, long-term extension trial and Phase 2 trial.

◦ Achieved positive results in CATALYST, our Phase 4 trial examining the prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes and the treatment of hypercortisolism in such patients with Korlym ® .

◦ Completed enrollment in ROSELLA, our pivotal Phase 3 trial of relacorilant combined with nab-paclitaxel in patients with recurrent platinum resistant ovarian cancer.

◦ Continued enrollment in MONARCH, our Phase 2b trial of miricorilant in patients with metabolic dysfunction-associated steatohepatitis (“MASH”).

• Advanced promising compounds from our portfolio of selective cortisol modulators towards the clinic.

• Strengthened our global patent portfolio.

### Executive Compensation 2024 Program Overview
The Compensation Committee and the Board determined that the Company and its named executive officers met aggressive goals in 2024, as evidenced by outstanding commercial success and significant progress in all of its clinical activities. In addition to annual performance, the committee also noted significant advances in the Company’s long-term outlook relative to its peers. Taking into account these accomplishments, as well as the Company’s unique business model and its compensation principles, the committee and the Board took the following actions with respect to the compensation of our named executive officers for 2024:

Base Salary. Effective February 1, 2024, the Compensation Committee recommended, and the Board approved, an approximately four percent increase to the annual base salary of Dr. Belanoff, Dr. Guyer and Messrs. Maduck, Mokari and Robb.

Bonuses . In accordance with our practice of awarding cash bonuses for the achievement of significant corporate goals, in March 2025, we paid bonuses to all employees of the Company, including our named executive officers, in recognition of the accomplishments described above.

Equity Awards . In February 2024, the Compensation Committee recommended, and the Board approved, the grant of options to each of our named executive officers. These grants